Showing 1,481 - 1,500 results of 100,888 for search '(( 5 we decrease ) OR ( 5 ((((step decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.63s Refine Results
  1. 1481
  2. 1482
  3. 1483

    Design, Synthesis, and Biological Evaluation of [1,2,5]Oxadiazolo[3,4‑<i>b</i>]pyridin-7-ol as Mitochondrial Uncouplers for the Treatment of Obesity and Metabolic Dysfunction-Assoc... by Mary A. Foutz (20361830)

    Published 2024
    “…Mitochondrial uncouplers such as BAM15 increase respiration and energy expenditure and have potential in treating a variety of metabolic diseases. In this study, we disclose the structure–activity relationship profile of 6-substituted [1,2,5]oxadiazolo[3,4-<i>b</i>]pyridin-7-ol derivatives of BAM15. …”
  4. 1484
  5. 1485

    MicroRNA expression profile in retina and choroid in oxygen-induced retinopathy model by Michel Desjarlais (6832442)

    Published 2019
    “…During OIR-induced vessel degeneration phase, miR-199a-3p, -199a-5p, -1b, -126a-3p displayed a robust decreased expression (> 85%) in the retina. …”
  6. 1486
  7. 1487

    FLIM-FRET measurements with KIRIN1 sensor detects relative changes in intracellular K<sup>+</sup>. by Xiaowen Jiang (8291814)

    Published 2024
    “…<b>(C)</b> FLIM-FRET measurements for intracellular K<sup>+</sup> levels in HEK293 Cells transfected with the CMV:KIRIN1 sensor and either CMV:Kcnk5bS345A-mCherry, CMV:Kcnk5bWT-mCherry, or CMV:Kcnk5bS345E-mCherry. …”
  8. 1488
  9. 1489
  10. 1490
  11. 1491
  12. 1492

    Drp1<sup>SD</sup> overexpression in Opa1 or Marf depleted type II NBs rescues the reduced mitochondrial membrane potential. by Dnyanesh Dubal (12085942)

    Published 2022
    “…<p>A, B: Representative images showing decreased TMRM intensity in <i>opa1</i> RNAi and <i>marf</i> RNAi expressing type II NBs. …”
  13. 1493
  14. 1494
  15. 1495
  16. 1496
  17. 1497
  18. 1498
  19. 1499
  20. 1500

    Treatment adoption and diffusion pattern. by Frédéric Galacteros (11105678)

    Published 2023
    “…In clinical studies, voxelotor has been shown to increase hemoglobin (Hb) and decrease hemolytic markers in patients with SCD. The objective of this study was to estimate the impact of voxelotor on the burden of SCD in France using a modeling approach, accounting for its anticipated adoption and diffusion over the next 5 years. …”